BRIEF published on 08/12/2025 at 07:35, 1 year 2 months ago Dermapharm Holding SE poursuit sa croissance au deuxième trimestre 2025 Prévisions De Revenus Croissance De L'EBITDA Produits Pharmaceutiques De Marque Dermapharm Performances Du Deuxième Trimestre 2025
BRIEF published on 08/12/2025 at 07:35, 1 year 2 months ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 1 year 2 months ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 1 year 3 months ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
BRIEF published on 06/26/2025 at 17:48, 1 year 3 months ago Dermapharm Holding SE approuve un dividende de 0,90 € par action Dividende Durabilité Assemblée Générale Annuelle Perspectives Financières Dermapharm
PRESS RELEASE published on 06/26/2025 at 17:43, 1 year 3 months ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share Dermapharm Holding SE's Annual General Meeting approves divident distribution of EUR 0.90 per share for 2024, confirms 2025 outlook and ratifies Board actions Annual General Meeting Financial Year 2024 Dividend Distribution Dermapharm Holding SE EUR 0.90 Per Share
BRIEF published on 05/15/2025 at 07:35, 1 year 4 months ago Dermapharm Holding SE répond aux attentes du premier trimestre 2025 et renforce ses prévisions pour l'ensemble de l'année Croissance Des Revenus Baisse De L'EBITDA Orientation Pour L'année Entière Produits Pharmaceutiques De Marque Dermapharm T1 2025
BRIEF published on 05/15/2025 at 07:35, 1 year 4 months ago Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast Revenue Growth Full-year Guidance EBITDA Decline Branded Pharmaceuticals Dermapharm Q1 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 1 year 4 months ago Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance Dermapharm Holding SE reports Q1 2025 results in line with projections, confirming full-year guidance. Revenue increases by 1.2% year-on-year to EUR 302.4 million Adjusted EBITDA Revenue Growth Dermapharm Holding SE Full-year Guidance Q1 2025 Results
BRIEF published on 03/28/2025 at 07:35, 1 year 6 months ago Les résultats financiers de Dermapharm en 2024 dépassent les attentes Augmentation Des Revenus Croissance De L'EBITDA Résultats Financiers 2024 Produits Pharmaceutiques De Marque Dermapharm
Published on 10/12/2026 at 22:01, 5 hours 9 minutes ago Fermi Announces Third Quarter 2026 Earnings Release and Call Date
Published on 10/12/2026 at 15:00, 12 hours 10 minutes ago Shelfie-Tech Announces Closing of Private Placement
Published on 10/12/2026 at 13:00, 14 hours 10 minutes ago U.S. Energy Secretary Chris Wright, EXIM Chairman John Jovanovic, Nebraska Governor Jim Pillen, Senators Deb Fischer and Pete Ricketts, and Congressman Adrian Smith to Visit NioCorp's Critical Minerals Mine Site
Published on 10/10/2026 at 04:45, 2 days 22 hours ago Immutable Holdings and Jorge Masvidal's Gamebred Fighting Championship (FC) Enter Into Definitive Agreement for Proposed Reverse Takeover Transaction and Listing on the TSXV
Published on 10/10/2026 at 02:03, 3 days 1 hour ago BrandPilot AI Announces Closing of Previously Announced Debt Settlement
Published on 10/12/2026 at 20:30, 6 hours 40 minutes ago Correction of a release from 29.09.2026 18:15 CET/CEST - Multi Units Luxembourg: NOTICE TO THE SHAREHOLDERS
Published on 10/12/2026 at 20:30, 6 hours 40 minutes ago Correction of a release from 02.10.2026 14:59 CET/CEST - Multi Units Luxembourg: NOTICE TO THE SHAREHOLDERS
Published on 10/12/2026 at 20:05, 7 hours 5 minutes ago SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
Published on 10/12/2026 at 19:10, 8 hours ago Cell Impact announces acceleration of previously communicated order from US customer
Published on 10/12/2026 at 19:00, 8 hours 10 minutes ago PATRIMOINE ET COMMERCE : Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 5 octobre 2026 au 9 octobre 2026
Published on 10/12/2026 at 17:59, 9 hours 10 minutes ago Reporting on share buyback transactions carried out between October 7 and October 9, 2026
Published on 10/12/2026 at 17:59, 9 hours 10 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain du 7 au 9 octobre 2026
Published on 10/12/2026 at 17:45, 9 hours 25 minutes ago Déclaration des transactions sur actions propres réalisées du 05/10/2026 au 11/10/2026
Published on 10/12/2026 at 17:45, 9 hours 25 minutes ago Déclaration hebdomadaire de rachat d'actions
